US 11,866,475 B2
Modified RNA encoding VEGF-A polypeptides, formulations, and uses relating thereto
Leif Karlsson Parinder, Mölndal (SE); Regina Desirée Fritsche Danielson, Mölndal (SE); Kenny Mikael Hansson, Mölndal (SE); Li Ming Gan, Mölndal (SE); Jonathan Clarke, Stockholm (SE); Ann-Charlotte Eva Egnell, Mölndal (SE); and Kenneth Randall Chien, Stockholm (SE)
Assigned to ModernaTX, Inc., Cambridge, MA (US)
Appl. No. 16/305,224
Filed by MODERNATX, INC, Cambridge, MA (US)
PCT Filed Jun. 6, 2017, PCT No. PCT/US2017/036188
§ 371(c)(1), (2) Date Nov. 28, 2018,
PCT Pub. No. WO2017/214175, PCT Pub. Date Dec. 14, 2017.
Claims priority of provisional application 62/432,005, filed on Dec. 9, 2016.
Claims priority of provisional application 62/411,091, filed on Oct. 21, 2016.
Claims priority of provisional application 62/346,979, filed on Jun. 7, 2016.
Prior Publication US 2020/0407411 A1, Dec. 31, 2020
Int. Cl. C07K 14/515 (2006.01); A61K 38/18 (2006.01); A61K 31/712 (2006.01); A61P 9/10 (2006.01); A61P 17/02 (2006.01); A61P 13/12 (2006.01); A61P 9/04 (2006.01); A61K 9/00 (2006.01); A61K 47/12 (2006.01)
CPC C07K 14/515 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0021 (2013.01); A61K 31/712 (2013.01); A61K 38/1866 (2013.01); A61K 47/12 (2013.01); A61P 9/10 (2018.01); A61P 17/02 (2018.01)] 26 Claims
 
1. A composition comprising a modified mRNA encoding a VEGF-A polypeptide of SEQ ID NO: 2 and a citrate saline buffer, wherein the citrate saline buffer is substantially free of divalent cations.